DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Mipomersen
Mipomersen
A Novel Therapeutic Drug for the Treatment of Familial Hypercholesterolemia, Hyperlipidaemia, and Hypercholesterolemia
Label (PDF)
Volanesorsen Fdaadvisory Committee Meeting Briefing Document
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Annexes of the Annual Report 2011
Mipomersen (KYNAMRO®) Monograph
Mipomersen Sodium Manufacturer1: Genzyme Corp. Drug Class1,2
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
203568Orig1s000
Ibm Micromedex® Carenotes Titles by Category
Kynamro Mipomersen MCP156
INTEGRATED REVIEW Executive Summary Interdisciplinary Assessment Appendices NDA211617 Nexlizet I Bempedoic Acid and Ezetimibe
Management of Lipids Beyond Statin Therapy
Study Protocol 1002-046 Amendment 1, 10 April 2017
Kynamro (Mipomersen) Policy Number: C3892-A
A Comparison of Mipomersen (Kynamroâ®) and Lomitapide (Juxtapidâ®): Medications for the Treatment of Homozygous Familial
Drug-Induced Diseases
Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log
Top View
The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: a Systematic Review and Meta-Analysis of Clinical Trials
Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
Antisense Oligonucleotide, Across Species S
Kynamro, INN-Mipomersen
Kynamro® (Mipomersen Sodium) Effective 4/1/2020
CT-16427 REPATHA REEVAL PIC AVIS3 CT16427.Pdf
WO 2016/127019 A2 11 August 2016 (11.08.2016) P O P C T
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
Annual Report 2013
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
UPMC Medicare 2016
Cell, Gene, & RNA Therapy Landscape
Study Protocol 1002-048 Amendment 2, 10 February 2017
211616Orig1s000
Bile Acid Sequestrants • Niacin • Fibrates • Mipomersen • Lomitapide • LDL Apheresis Evidence for Treating All FH Patients
Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
Treatment of Hypertriglyceridemia: a Review of Current Options
Mipomersen (Kynamro) Reference Number: CP.PHAR.284 Effective Date: 10.16 Last Review Date: 02.20 Line of Business: Commercial, Medicaid Revision Log
Antisense Oligonucleotides: an Emerging Area in Drug Discovery and Development
203568Orig1s000
Liver Histology During Mipomersen Therapy for Severe Hypercholesterolemia
FDA Briefing Document Endocrinologic and Metabolic
Kynamro (Mipomersen Sodium)
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Cholesterol Lowering Agents
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log
Effects of Mipomersen in Combination with Lomitapide in Homozygous Familial Hypercholesterolemia
Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
ERX.SPA.171 Mipomersen (Kynamro)
( 12 ) United States Patent
Mipomersen and Lomitapide Background
Study Protocol 1002FDC-053 Amendment 1, 18 October 2017
Non-Interventional Study Protocol
203568Orig1s000
Methodik Der ATC-Klassifikation Und DDD-Festlegung Für Den Deutschen